rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-182-189rsp-2074Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYТУЧНЫЕ КЛЕТКИ – КЛЮЧЕВЫЕ УЧАСТНИКИ ПАТОГЕНЕЗА ИММУНОВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙMAST CELLS ARE KEY PARTICIPANTS IN THE PATHOGENESIS OF IMMUNOINFLAMMATORY DISEASESБаглайЕ. ОBaglayE. O.bagl86@mail.ruДубиковА. И.DubikovA. I.

Доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии

bagl86@mail.ruТихоокеанский государственный медицинский университет, ВладивостокРоссияPacific State Medical University, VladivostokRussian Federation201529042015532182189Copyright © Баглай Е.О., Дубиков А.И., 20152015Баглай Е.О., Дубиков А.И.Baglay E.O., Dubikov A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2074

Тучные клетки являются неотъемлемым звеном патогенетической цепочки  иммунного  воспаления в тканях организма  при различных заболеваниях. Недостаточно изученными остаются механизмы  реализации провоспалительных эффектов тучных клеток. Их изучение может способствовать оптимизации терапии различных заболеваний, в том числе хронических  артритов.

Mast cells are an integral component of the pathogenetic  chain of immune inflammation in the body's tissues in different diseases. The mechanisms  underlying the proinflammatory effects of mast cells remain inadequately investigated. Their study may contribute to the optimization of therapy for different diseases, including chronic arthritis.

тучные клеткивоспалениеревматоидный артритаутоиммунитетmast cellsinflammationrheumatoid arthritisautoimmunityReferencesOkayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97–115. doi: 10.1385/IR:34:2:97Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97–115. doi: 10.1385/IR:34:2:97Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann NY Acad Sci. 2008;1143:83–104. doi: 10.1196/annals.1443.023Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann NY Acad Sci. 2008;1143:83–104. doi: 10.1196/annals.1443.023Metz M, Maurer M. Mast cells – key effector cells in immune responses. Trends Immunol. 2007;28:234–41. doi: 10.1016/j.it.2007.03.003Metz M, Maurer M. Mast cells – key effector cells in immune responses. Trends Immunol. 2007;28:234–41. doi: 10.1016/j.it.2007.03.003Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9:1215–23. doi: 10.1038/ni.f.216Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9:1215–23. doi: 10.1038/ni.f.216Kneilling M, Rocken M. Mast cells: novel clinical perspectives from recent insights. Exp Dermatol. 2009;18:488–96. doi: 10.1111/j.1600-0625.2009.00860.xKneilling M, Rocken M. Mast cells: novel clinical perspectives from recent insights. Exp Dermatol. 2009;18:488–96. doi: 10.1111/j.1600-0625.2009.00860.xSayed BA, Christy A, Quirion MR, Brown MA. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008;26:705–39. doi: 10.1146/annurev.immunol.26.021607.090320Sayed BA, Christy A, Quirion MR, Brown MA. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008;26:705–39. doi: 10.1146/annurev.immunol.26.021607.090320Wei OL, Hilliard A, Kalman D, Sherman M. Mast cells limit systemic bacterial dissemination but not colitis in response to Citrobacter rodentium. Infect Immun. 2005;73:1978–85. doi: 10.1128/IAI.73.4.1978-1985.2005Wei OL, Hilliard A, Kalman D, Sherman M. Mast cells limit systemic bacterial dissemination but not colitis in response to Citrobacter rodentium. Infect Immun. 2005;73:1978–85. doi: 10.1128/IAI.73.4.1978-1985.2005Velin D, Bachmann D, Bouzourene H, Michetti P. Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology. 2005;129:142–55. doi: 10.1053/j.gastro.2005.04.010Velin D, Bachmann D, Bouzourene H, Michetti P. Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology. 2005;129:142–55. doi: 10.1053/j.gastro.2005.04.010Lawrence CE, Paterson YY, Wright SH, et al. Mouse mast cell protease-1 is required for the enteropathy induced by gastrointestinal helminth infection in the mouse. Gastroenterology. 2004;127:155–65. doi: 10.1053/j.gastro.2004.04.004Lawrence CE, Paterson YY, Wright SH, et al. Mouse mast cell protease-1 is required for the enteropathy induced by gastrointestinal helminth infection in the mouse. Gastroenterology. 2004;127:155–65. doi: 10.1053/j.gastro.2004.04.004Anthony RM, Rutitzky LI, Urban Jr JF, et al. Protective immune mechanisms in helminth infection. Nat Rev Immunol. 2007;7:975–87. doi: 10.1038/nri2199Anthony RM, Rutitzky LI, Urban Jr JF, et al. Protective immune mechanisms in helminth infection. Nat Rev Immunol. 2007;7:975–87. doi: 10.1038/nri2199Sundstrom JB, Hair GA, Ansari AA, et al. IgE-Fc-epsilon RI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells. J Immunol. 2009;182:6401–9. doi: 10.4049/jimmunol.0801481Sundstrom JB, Hair GA, Ansari AA, et al. IgE-Fc-epsilon RI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells. J Immunol. 2009;182:6401–9. doi: 10.4049/jimmunol.0801481Taub DD, Mikovits JA, Nilsson G, et al. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4. Cell Immunol. 2004;230:65–80. doi: 10.1016/j.cellimm.2004.09.005Taub DD, Mikovits JA, Nilsson G, et al. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4. Cell Immunol. 2004;230:65–80. doi: 10.1016/j.cellimm.2004.09.005Becker Y. HIV-1 induced AIDS is an allergy and the allergen is the Shed gp120 – a review, hypothesis, and implications. Virus Genes. 2004;28:319–31. doi: 10.1023/B:VIRU.0000025778.56507.61Becker Y. HIV-1 induced AIDS is an allergy and the allergen is the Shed gp120 – a review, hypothesis, and implications. Virus Genes. 2004;28:319–31. doi: 10.1023/B:VIRU.0000025778.56507.61Grimbaldeston MA, Chen CC, Piliponsky AM, et al. Mast celldeficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167:835–48. doi: 10.1016/S0002-9440(10)62055-XGrimbaldeston MA, Chen CC, Piliponsky AM, et al. Mast celldeficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167:835–48. doi: 10.1016/S0002-9440(10)62055-XSteinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85:299–302. doi: 10.1016/S0092-8674(00)81107-1Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85:299–302. doi: 10.1016/S0092-8674(00)81107-1Jager A, Kuchroo VK. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol. 2010;72:173–84. doi: 10.1111/j.1365-3083.2010.02432.xJager A, Kuchroo VK. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol. 2010;72:173–84. doi: 10.1111/j.1365-3083.2010.02432.xFletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11. doi: 10.1111/j.1365-2249.2010.04143.xFletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11. doi: 10.1111/j.1365-2249.2010.04143.xNeuman J. Ueber das Vorkommen der sogneannten «Mastzellen» bei pathologischen Veraenderungen des Gehirns. Arch Pathol Anat Physiol Virchows. 1890;122:378–81.Neuman J. Ueber das Vorkommen der sogneannten «Mastzellen» bei pathologischen Veraenderungen des Gehirns. Arch Pathol Anat Physiol Virchows. 1890;122:378–81.Bebo Jr BF, Yong T, Orr EL, Linthicum DS. Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J Neurosci Res. 1996;45:340–8. doi: 10.1002/(SICI)1097-4547(19960815)45:4<340::AID-JNR3>3.0.CO;2-9Bebo Jr BF, Yong T, Orr EL, Linthicum DS. Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J Neurosci Res. 1996;45:340–8. doi: 10.1002/(SICI)1097-4547(19960815)45:4<340::AID-JNR3>3.0.CO;2-9Ibrahim MZ, Reder AT, Lawand R, et al. The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996;70:131–8. doi: 10.1016/S0165-5728(96)00102-6Ibrahim MZ, Reder AT, Lawand R, et al. The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996;70:131–8. doi: 10.1016/S0165-5728(96)00102-6Rozniecki JJ, Hauser SL, Stein M, et al. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol. 1995;37:63–6. doi: 10.1002/ana.410370112Rozniecki JJ, Hauser SL, Stein M, et al. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol. 1995;37:63–6. doi: 10.1002/ana.410370112Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005;12:167–81. doi: 10.1016/j.pathophys.2005.07.011Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005;12:167–81. doi: 10.1016/j.pathophys.2005.07.011Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297:1689–92. doi: 10.1126/science.1073176Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297:1689–92. doi: 10.1126/science.1073176Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184:3336–40. doi: 10.4049/jimmunol.0903566Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184:3336–40. doi: 10.4049/jimmunol.0903566Sandler C, Lindstedt KA, Joutsiniemi S, et al. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm Res. 2007;56:230–9. doi: 10.1007/s00011-007-6135-1Sandler C, Lindstedt KA, Joutsiniemi S, et al. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm Res. 2007;56:230–9. doi: 10.1007/s00011-007-6135-1Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 2009;182:647–56. doi: 10.4049/jimmunol.182.1.647Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 2009;182:647–56. doi: 10.4049/jimmunol.182.1.647Sawamukai N, Yukawa S, Saito K, et al. Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. Arthritis Rheum. 2010;62:952–9. doi: 10.1002/art.27331Sawamukai N, Yukawa S, Saito K, et al. Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. Arthritis Rheum. 2010;62:952–9. doi: 10.1002/art.27331Palmer HS, Kelso EB, Lockhart JC, et al. Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells. Arthritis Rheum. 2007;56:3532–40. doi: 10.1002/art.22936Palmer HS, Kelso EB, Lockhart JC, et al. Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells. Arthritis Rheum. 2007;56:3532–40. doi: 10.1002/art.22936Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigeninduced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105:10913–8. doi: 10.1073/pnas.0801898105Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigeninduced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105:10913–8. doi: 10.1073/pnas.0801898105Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2010. С. 296–8. [Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-media; 2010. P. 296–8].Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2010. С. 296–8. [Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-media; 2010. P. 296–8].Дубиков АИ. Апоптоз клеток синовиальной оболочки у больных ревматоидным артритом. Тихоокеанский медицинский журнал. 2008;(4):20–3. [Dubikov AI. Apoptosis in the synovium of patients with rheumatoid arthritis. Tikhookeanskii meditsinskii zhurnal. 2008;(4):20–3. (In Russ.)].Дубиков АИ. Апоптоз клеток синовиальной оболочки у больных ревматоидным артритом. Тихоокеанский медицинский журнал. 2008;(4):20–3. [Dubikov AI. Apoptosis in the synovium of patients with rheumatoid arthritis. Tikhookeanskii meditsinskii zhurnal. 2008;(4):20–3. (In Russ.)].Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibodyinduced arthritis. J Immunol. 2010;184:2620–6. doi: 10.4049/jimmunol.0902685Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibodyinduced arthritis. J Immunol. 2010;184:2620–6. doi: 10.4049/jimmunol.0902685Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allergy Immunol. 2007;33:144–55. doi: 10.1007/s12016-007-0029-4Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allergy Immunol. 2007;33:144–55. doi: 10.1007/s12016-007-0029-4Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108:1151–8. doi: 10.1172/JCI11494Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108:1151–8. doi: 10.1172/JCI11494Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480–8. doi: 10.1172/JCI116856Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480–8. doi: 10.1172/JCI116856Dvorak AM, Mihm Jr MC, Osage JE, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies fromDvorak AM, Mihm Jr MC, Osage JE, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies fromonepatient. J Invest Dermatol. 1982;78:91–101. doi: 10.1111/1523-1747.ep12505711onepatient. J Invest Dermatol. 1982;78:91–101. doi: 10.1111/1523-1747.ep12505711Baba T, Sonozaki H, Seki K, et al. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol. 1976;116:112–6.Baba T, Sonozaki H, Seki K, et al. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol. 1976;116:112–6.Katayama I, Doi T, Nishioka K. High histamine level in the blister fluid of bullous pemphigoid. Arch Dermatol Res. 1984;276:126–7. doi: 10.1007/BF00511070Katayama I, Doi T, Nishioka K. High histamine level in the blister fluid of bullous pemphigoid. Arch Dermatol Res. 1984;276:126–7. doi: 10.1007/BF00511070D'Auria L, Pietravalle M, Cordiali-Fei P, Ameglio F. Increased tryptase and myeloperoxidase levels in blister fluids of patients with bullous pemphigoid: correlations with cytokines, adhesion molecules and anti-basement membrane zone antibodies. Exp Dermatol. 2000;9:131–7. doi: 10.1034/j.1600-0625.2000.009002131.xD'Auria L, Pietravalle M, Cordiali-Fei P, Ameglio F. Increased tryptase and myeloperoxidase levels in blister fluids of patients with bullous pemphigoid: correlations with cytokines, adhesion molecules and anti-basement membrane zone antibodies. Exp Dermatol. 2000;9:131–7. doi: 10.1034/j.1600-0625.2000.009002131.xBrockow K, Abeck D, Hermann K, Ring J. Tryptase concentration in skin blister fluid from patients with bullous skin conditions. Arch Dermatol Res. 1996;288:771–3. doi: 10.1007/BF02505295Brockow K, Abeck D, Hermann K, Ring J. Tryptase concentration in skin blister fluid from patients with bullous skin conditions. Arch Dermatol Res. 1996;288:771–3. doi: 10.1007/BF02505295Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–300. doi: 10.1038/nature08933Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–300. doi: 10.1038/nature08933Geoffrey R, Jia S, Kwitek AE, et al. Evidence of a functional role for mast cells in the development of type 1diabetes mellitus in the BioBreeding rat. J Immunol. 2006;177:7275–86. doi: 10.4049/jimmunol.177.10.7275Geoffrey R, Jia S, Kwitek AE, et al. Evidence of a functional role for mast cells in the development of type 1diabetes mellitus in the BioBreeding rat. J Immunol. 2006;177:7275–86. doi: 10.4049/jimmunol.177.10.7275Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in non obese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–900. doi: 10.1073/pnas.0810246105Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in non obese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–900. doi: 10.1073/pnas.0810246105Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet induced obesity and diabetes in mice. Nat Med. 2009;15:940–5. doi: 10.1038/nm.1994Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet induced obesity and diabetes in mice. Nat Med. 2009;15:940–5. doi: 10.1038/nm.1994Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849–59. doi: 10.1038/nri2889Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849–59. doi: 10.1038/nri2889Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771–81. doi: 10.1016/j.immuni.2008.08.018Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771–81. doi: 10.1016/j.immuni.2008.08.018Kashyap M, Thornton AM, Norton SK, et al. Cutting edge: CD4 T cell-mast cell interaction salter IgE receptor expression and signaling. J Immunol. 2008;180:2039–43. doi: 10.4049/jimmunol.180.4.2039Kashyap M, Thornton AM, Norton SK, et al. Cutting edge: CD4 T cell-mast cell interaction salter IgE receptor expression and signaling. J Immunol. 2008;180:2039–43. doi: 10.4049/jimmunol.180.4.2039Piconese S, Gri G, Tripodo C, et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood. 2009;114:2639–48. doi: 10.1182/blood-2009-05-220004Piconese S, Gri G, Tripodo C, et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood. 2009;114:2639–48. doi: 10.1182/blood-2009-05-220004De Vries VC, Wasiuk A, Bennett KA, et al. Mast cell degranulation breaks peripheral tolerance. Am J Transplant. 2009;9:2270–80. doi: 10.1111/j.1600-6143.2009.02755.xDe Vries VC, Wasiuk A, Bennett KA, et al. Mast cell degranulation breaks peripheral tolerance. Am J Transplant. 2009;9:2270–80. doi: 10.1111/j.1600-6143.2009.02755.xVon Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol. 2008 Aug 15;181(4):2799–805.Von Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol. 2008 Aug 15;181(4):2799–805.Forward NA, Furlong SJ, Yang Y, et al. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol. 2009;183:3014–22. doi: 10.4049/jimmunol.0802509Forward NA, Furlong SJ, Yang Y, et al. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol. 2009;183:3014–22. doi: 10.4049/jimmunol.0802509Hemdan NY, Birkenmeier G, Wichmann AM, et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev. 2010;9:785–92. doi: 10.1016/j.autrev.2010.07.003Hemdan NY, Birkenmeier G, Wichmann AM, et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev. 2010;9:785–92. doi: 10.1016/j.autrev.2010.07.003Tripodo C, Gri G, Piccaluga PP, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177:792–802. doi: 10.2353/ajpath.2010.091286Tripodo C, Gri G, Piccaluga PP, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177:792–802. doi: 10.2353/ajpath.2010.091286Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20:4–12. doi: 10.1038/cr.2009.138Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20:4–12. doi: 10.1038/cr.2009.138Kawakami T, Kitaura J, Xiao W, Kawakami Y. IgE regulation of mast cell survival and function. Novartis Found Symp. 2005;271:100–7; discussion 108–14, 145–51.Kawakami T, Kitaura J, Xiao W, Kawakami Y. IgE regulation of mast cell survival and function. Novartis Found Symp. 2005;271:100–7; discussion 108–14, 145–51.Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev. 2007;217:206–21. doi: 10.1111/j.1600-065X.2007.00510.xMalbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev. 2007;217:206–21. doi: 10.1111/j.1600-065X.2007.00510.xMerluzzi S, Frossi B, Gri G, et al. Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA secreting plasma cells. Blood. 2010;115:2810–7. doi: 10.1182/blood-2009-10-250126Merluzzi S, Frossi B, Gri G, et al. Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA secreting plasma cells. Blood. 2010;115:2810–7. doi: 10.1182/blood-2009-10-250126Minagar A, Shapshak P, Fujimura R, et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci. 2002;202:13–23. doi: 10.1016/S0022-510X(02)00207-1Minagar A, Shapshak P, Fujimura R, et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci. 2002;202:13–23. doi: 10.1016/S0022-510X(02)00207-1Kim DY, Jeoung D, Ro JY. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J Immunol. 2010;185:273–83. doi: 10.4049/jimmunol.1000991Kim DY, Jeoung D, Ro JY. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J Immunol. 2010;185:273–83. doi: 10.4049/jimmunol.1000991Bulanova E, Bulfone-Paus S. P2 receptor-mediated signaling in mast cell biology. Purinergic Signa. 2010;6(1):3–17. doi: 10.1007/s11302-009-9173-zBulanova E, Bulfone-Paus S. P2 receptor-mediated signaling in mast cell biology. Purinergic Signa. 2010;6(1):3–17. doi: 10.1007/s11302-009-9173-zHudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol. 2008;84:631–43. doi: 10.1189/jlb.1207830Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol. 2008;84:631–43. doi: 10.1189/jlb.1207830Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009;9(6):440–7. doi: 10.1038/nri2548Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009;9(6):440–7. doi: 10.1038/nri2548Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79–87. doi: 10.1016/j.tcb.2005.12.005Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79–87. doi: 10.1016/j.tcb.2005.12.005Denhardt DT, Burger EH, Kazanecki C, et al. Osteopontin-deficient bone cells are defective in their ability to produce NO in response to pulsatile fluid flow. Biochem Biophys Res Commun. 2001;288:448–53. doi: 10.1006/bbrc.2001.5780Denhardt DT, Burger EH, Kazanecki C, et al. Osteopontin-deficient bone cells are defective in their ability to produce NO in response to pulsatile fluid flow. Biochem Biophys Res Commun. 2001;288:448–53. doi: 10.1006/bbrc.2001.5780O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol. 2000;68:495–502.O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol. 2000;68:495–502.Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood. 2005;106:946–55. doi: 10.1182/blood-2004-08-3228Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood. 2005;106:946–55. doi: 10.1182/blood-2004-08-3228Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol. 2006;7(5):498–506. doi: 10.1038/ni1327Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol. 2006;7(5):498–506. doi: 10.1038/ni1327Diao H, Kon S, Iwabuchi K, et al. Osteopontin as a mediator of NKT cell function in T cell mediated liver diseases. Immunity. 2004;21:539–50. doi: 10.1016/j.immuni.2004.08.012Diao H, Kon S, Iwabuchi K, et al. Osteopontin as a mediator of NKT cell function in T cell mediated liver diseases. Immunity. 2004;21:539–50. doi: 10.1016/j.immuni.2004.08.012Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 2008;38:489–99. doi: 10.1002/eji.200737057Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 2008;38:489–99. doi: 10.1002/eji.200737057O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–80. doi: 10.1002/jcp.20061O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–80. doi: 10.1002/jcp.20061Reinke E, Fabry Z. Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol Lett. 2006;104:102–9. doi: 10.1016/j.imlet.2005.11.009Reinke E, Fabry Z. Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol Lett. 2006;104:102–9. doi: 10.1016/j.imlet.2005.11.009Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563–8. doi: 10.1016/j.tips.2004.09.007Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563–8. doi: 10.1016/j.tips.2004.09.007Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol. 1993;150:4478–85.Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol. 1993;150:4478–85.Oboki K, Ohno T, Kajiwara N, et al. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int. 2010;59:143–60. doi: 10.2332/allergolint.10-RAI-0186Oboki K, Ohno T, Kajiwara N, et al. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int. 2010;59:143–60. doi: 10.2332/allergolint.10-RAI-0186Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008;9:1006–12. doi: 10.1038/embor.2008.145Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008;9:1006–12. doi: 10.1038/embor.2008.145Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103–10. doi: 10.1038/nri2692Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103–10. doi: 10.1038/nri2692

The authors declare that there are no conflicts of interest present.